The drastic reduction in indirect costs is not a path to innovation or cost savings — it’s a threat to U.S.’s position as global leader in medical research.
The National Institutes of Health announced Friday that it will impose a 15% cap on payment for the “indirect costs” on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback